Mission statement

DEADLINE ALERT for OPEN, SQ, SMIT, ARGO: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

Retrieved on: 
Wednesday, November 9, 2022
GLOBE, Name, Investment, Telephone, Risk, Argo, Schmitt, Defendant, People's Law Office, Class, Suite, Mission statement, Time, Company, Law, Security (finance), Public relations

BENSALEM, Pa., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.

Key Points: 
  • BENSALEM, Pa., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.
  • Investors have until the deadlines listed below to file a lead plaintiff motion.
  • Investors suffering losses on their investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in these class actions at 888-638-4847 or by email to [email protected] .
  • Law Offices of Howard G. Smith

MaxCyte Reports Third Quarter 2022 Financial Results

Retrieved on: 
Wednesday, November 9, 2022
Investor, Review, Private Securities Litigation Reform Act, SPL, Marketing, Risk, Investment, U.S. Securities and Exchange Commission, Adoption, Depreciation, Mission statement, Annual report, Net, EBITDA, Cell, GAAP, Engineering, Expert, Therapy, Security (finance), COVID-19, Video game, Fine chemical, Bank

ROCKVILLE, Md., Nov. 09, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support innovative, cell-based research, today announced financial results for the third quarter ended September 30, 2022.

Key Points: 
  • Total revenue for the third quarter of 2022 was $10.6 million, compared to $10.1 million in the third quarter of 2021, representing an increase of 5%.
  • Operating expenses for the third quarter of 2022 were $17.0 million, compared to operating expenses of $11.6 million in the third quarter of 2021.
  • Third quarter 2022 net loss was $6.4 million compared to net loss of $2.7 million for the same period in 2021.
  • EBITDA, a non-GAAP measure, was a loss of $7.1 million for the third quarter of 2022, compared to a loss of $2.4 million for the third quarter of the prior year.

ORYZON Announces FDA Clearance of IND to Initiate a Collaborative Phase II Basket Study with Iadademstat in R/R Patients with Neuroendocrine Carcinomas (NECs)

Retrieved on: 
Wednesday, November 9, 2022
IND, Communication, Research, CNMV, Development, Sale, Person, NEC Laboratories America, Survival, Fox Chase Cancer Center, CRADA, Associate, Squamous cell carcinoma, Phase II, NETS, Forward-looking statement, Prevalence, Azacitidine, B cell, ISIN, FLT3, Prospectus, FCCC, Mercado, Cancer, Gastrointestinal tract, AML, Patient, MD, NCI, NET, Investigational New Drug, Cooperative research and development agreement, Hematological Cancer Research Investment and Education Act, Medulloblastoma, EHA, Acute myeloid leukemia, NEC, Mission statement, Public expenditure, Growth, FDA, GLOBE, Carcinoma, ORY, ESMO, Wilms' tumor, Spanish, Safety, LSD1, Genomics, ALICE, Prognosis, Pharmaceutical industry, SCLC, EU

Patients often rapidly develop progressive disease after first line cytotoxic chemotherapy and lack clearly efficacious second line treatment options.

Key Points: 
  • Patients often rapidly develop progressive disease after first line cytotoxic chemotherapy and lack clearly efficacious second line treatment options.
  • Response rates for NECs and SCLC in second line are generally less than 5% and 20%, respectively, and survival is measured in months.
  • There are very few treatment options for these patients and even fewer trials, which makes this effort even more important.
  • In total iadademstat has been dosed so far to more than 100 cancer patients in four clinical trials.

EURO Ressources reports earnings for the third quarter and nine months ended September 30, 2022

Retrieved on: 
Wednesday, November 9, 2022
Director, Mining, Silver, Iamgold, Gold, Supreme court, EURO, Board, Securities Act of 1933, Mission statement, IAMGOLD, News, Vinnytsia Administrative Court of Appeal, International, French Government of the Hundred Days, Company, Largest gold companies, Investment, Life, Compagnie minière de l'Ogooué, Energy Independence and Security Act of 2007, SEDAR, Administrative court, Royalty, COVID-19, Income, Video game, Audit, Holding company, Security (finance), Lithium, Cryptocurrency, Animal, Nordgold, Montagne, Orea, Rosebel gold mine

THIRD QUARTER AND NINE MONTHS ENDED SEPTEMBER 30, 2022

Key Points: 
  • THIRD QUARTER AND NINE MONTHS ENDED SEPTEMBER 30, 2022
    Paris, France, November 9, 2022: EURO Ressources S.A. (EURO or the Company) (Paris:EUR) today announced its unaudited statutory interim financial results prepared in accordance with International Financial Reporting Standards (IFRS) for the nine months ended September30, 2022.
  • No impairment charges were recorded in the statement of earnings for the period ended September 30, 2022.
  • Nine months ended September30, 2022 compared to the same period in 2021 (IFRS)
    Under IFRS, EURO reported a net profit of 9.3 million (0.149 per share) for the nine months ended September 30, 2022 compared to 5.0 million (0.080 per share) for the nine months ended September 30, 2021.
  • Revenues were only attributable to the Rosebel royalty for the first nine months ended September 30, 2022 and 2021.

Martine Gerow joins the Board of Directors of SCOR

Retrieved on: 
Wednesday, November 9, 2022
Director, Annual general meeting, Mass meeting, Board of directors, Audit committee, American Express Global Business Travel, CWT (company), Board, Committee, Paris, Travel, Mission statement, SCOR, CFO, MBA, HEC Paris, Business, Management, Audit

On November 8, 2022, the Board of Directors of SCOR decided, upon proposal of the Nomination Committee, to co-opt Martine Gerow, Chief Financial Officer of American Express Global Business Travel, as a director.

Key Points: 
  • On November 8, 2022, the Board of Directors of SCOR decided, upon proposal of the Nomination Committee, to co-opt Martine Gerow, Chief Financial Officer of American Express Global Business Travel, as a director.
  • Martine Gerow also joins the Strategic Committee, the Audit Committee, and the Sustainability Committee.
  • The Board has already determined that Martine Gerow meets the required independence criteria.
  • Denis Kessler, Chairman of SCOR, comments: "I am delighted that the Board of Directors can henceforth benefit from Martine Gerows expertise, skills and experience.

Unisys Corporation Investor Alert: Kaplan Fox Investigates Potential Securities Fraud

Retrieved on: 
Tuesday, November 8, 2022
GLOBE, NYSE, Calendar, FOX, Disclosure, Communication, Mission statement, Company, Audit, Committee on Finance, Unisys

NEW YORK, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP ( www.kaplanfox.com ) is investigating claims on behalf of investors of Unisys Corporation (Unisys or the Company) (NYSE: UIS).

Key Points: 
  • NEW YORK, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP ( www.kaplanfox.com ) is investigating claims on behalf of investors of Unisys Corporation (Unisys or the Company) (NYSE: UIS).
  • WHY CONTACT KAPLAN FOX - Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey.
  • With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand.
  • For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com .

Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed on Behalf of Polished.com, Inc. (POL) Investors and Encourages Investors to Contact the Firm Before December 30, 2022

Retrieved on: 
Tuesday, November 8, 2022
GLOBE, NYSE American, NYSE, LLP, Mission statement, SEC, Failure, News, Compliance, Douglas v. U.S. District Court ex rel Talk America, Company, IPO, District court, Court, Kirby, Security (finance), Private investigator, Polished

Investors have until December 30, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until December 30, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • The Company offers microwave ovens, grills, fridges, dishwashers, dryers, space heaters, rugs, garbage disposals, furniture, and other home improvement products.
  • On this news, the price of Polished shares declined from $0.80 to close at $0.74 on August 26, 2022.
  • Kirby McInerney LLP is a New York-based plaintiffs law firm concentrating in securities, antitrust, whistleblower, and consumer litigation.

ROSEN, A TOP RANKED FIRM, Encourages Schmitt Industries, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action Filed by the Firm – SMIT

Retrieved on: 
Tuesday, November 8, 2022
Titan, GLOBE, Company, SMIT, Class, Mission statement, Advertising, NASDAQ, Court, I-Space (Chinese company), Insurance, Tobacco

WHAT TO DO NEXT: To join the Schmitt Industries class action, go to https://rosenlegal.com/submit-form/?case_id=8823 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Schmitt Industries class action, go to https://rosenlegal.com/submit-form/?case_id=8823 or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Unisys Corporation (UIS) Investors with Significant Losses to Contact Firm’s Attorneys, Firm Investigating Possible Securities Law Violations

Retrieved on: 
Tuesday, November 8, 2022
Mission statement, SEC, Communication, News, Steve Berman (lawyer), Audit committee, Fraud, Person, Disclosure, Company, Program, UIS, Audit, Pharmaceutical industry, Unisys

This news sent the price of Unisys shares crashing 48% lower in a single trading day.

Key Points: 
  • This news sent the price of Unisys shares crashing 48% lower in a single trading day.
  • Were focused on investors losses and whether Unisys may have violated its disclosure obligations, said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • If you invested in Unisys and have significant losses, or have knowledge that may assist the firms investigation, click here to discuss your legal rights with Hagens Berman .
  • Hagens Berman is a global plaintiffs rights complex litigation law firm focusing on corporate accountability through class-action law.

Medexus Announces Strongest Quarter in Company History with Fiscal Q2 2023 Revenue of US$27.7 Million, a 55% Increase Over Fiscal Q2 2022

Retrieved on: 
Tuesday, November 8, 2022
GLOBE, Rheumatoid arthritis, Meningioma, Aminolevulinic acid, Marketing, Investment, CDH, Calendar, Treosulfan, World Health Organization, Acceleration, MAT, Customer service, Webcast, Research, PAP, Glioma, Health Canada, Hematology, Mission statement, IQVIA, Hematopoietic stem cell transplantation, Safety, Allergy, EBITDA, Clinical trial, Patent, Patient, Growth, TSX, SEDAR, NDA, Blood, FDA, Pharmaceutical industry, Video game, Cryptocurrency, Risk management, Rupal State, Collaboration, Methotrexate

TORONTO and CHICAGO, Nov. 08, 2022 (GLOBE NEWSWIRE) --  Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company’s second fiscal quarter ended September 30, 2022. All dollar amounts in this press release are in United States dollars unless specified otherwise.

Key Points: 
  • Record total revenue of $27.7 million, a year-over-year increase of 55%, and a quarter-over-quarter increase of 20%.
  • This represents the strongest fiscal quarter in Medexuss history.
  • The primary drivers for this substantial year-over-year improvement were increases in revenues, a reduction in research & development costs, and an increase in gross margin.
  • Marcel Konrad, Chief Financial Officer of Medexus, further noted, During the second quarter we delivered an increase in our cash position versus previous quarter and generated positive operating cash flow this quarter.